ProMIS Neurosciences Inc (
TSX: PMN,
OTCQB: ARFXF,
Forum) announced today that it has commenced a groundbreaking Cohort Study intended to evaluate the prevalence of different strains of Amyloid beta (Ab)prions in patients with Alzheimer’s disease (AD). First results are anticipated in the first quarter of 2017.
The Study is being conducted in the laboratories of the Company’s CSO, Dr. Neil Cashman. The study will employ cerebrospinal fluid samples of more than 100 patients with dementia, collected over an eight-year period by Dr. Robin Hsuing, Associate Professor of Neurology at the University of British Columbia. The date accompanying these samples may also lead to the identification of prion strains which are associated with more rapid disease progression. Further information can be found
here.
ProMIS was recently in the news earlier this month when it announced
five “novel” antibody targets which met the ideal target profile for Alzheimer’s disease.
The Company has 181 million shares outstanding and a market cap of $25.4 million.
FULL DISCLOSURE: ProMIS Neursciences Inc is a paid client of Stockhouse Publishing.